Argenx will pay $550 million to acquire Unnatural Products’ macrocyclic peptide technology, according to BioPharma Dive. The platform is intended to help Argenx develop oral, durable medicines for serious immune-mediated diseases.
This move could influence how other pharma companies approach drug development for immune conditions. Senior executives should consider the implications for R&D investment and future competition in this space.
